HCC Cholate- Hepatic functional deterioration after radiation therapy for hepatocellular carcinoma measured by hepatic cholate clearance
Enrolling By Invitation
18 years - 99 years
All
Phase
1
40 participants needed
1 Location
Brief description of study
In this study, subjects diagnosed with liver cancer undergo the HepQuant SHUNT diagnostic assay as a means to determine liver function. The results of this assay will potentially inform radiation treatment.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Hepatocellular carcinoma,Liver cancer,Childs-Pugh B
-
Age: 18 years - 99 years
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 843529
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
